Brian McGrory, MD
Adult Reconstructive Orthopaedic Surgery · Falmouth, MENPI 1396746426
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $311,979 of the $423,563 with a category attached, or 73.7%. Smith+Nephew accounts for 99.8% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $139,189, 3.2 times the $43,521 reported in 2019.
Across 173 payments — averaging $2448.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$423K
- Zimmer Biomet$665
- Stryker$18
What the payments were for
- Royalty or licence$311,97974%
- Consulting fees$25,4816%
- Speaking & faculty fees$68,32016%
- Travel & lodging$12,4233%
- Food & beverage$5,1841%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 161 | $422,880 |
| Zimmer Biomet | 11 | $665 |
| Stryker | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Anthology$200,078
- EVOS$161,291
- POLARSTEM$73,281
- Journey II$49,895
- POLARCUP$41,228
- OR3O$32,037
- POLAR3$31,728
- R3$27,355
- Navio Surgical System$18,752
- REDAPT Revision Hip System$18,457
- Oxinium Hips$16,777
- REAL INTELLIGENCE$14,516
- Tandem$9,140
- OR3O Dual Mobility$9,132
- Journey II BCS$7,063
- Journey II CR$6,910
- JOURNEY II UK$6,910
- CORI$4,000
- BIRMINGHAM HIP$2,910
- R3 ACETABULAR$2,359
How this compares
Too few adult reconstructive orthopaedic surgery providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin | 147 | $144 |
| Methylprednisolone | 12 | $91 |
| Clindamycin Hcl | 20 | $40 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Falmouth
- Michael RobertsFalmouth$56K
- Joseph YoungFalmouth$16K
- Justin KuetherFalmouth$10K
- Donald EndrizziFalmouth$107
- Michael BeckerFalmouth$90
- Stephen WalshBangor$745K
- Zafar AhmadLewiston$14K
- Michael DefranceAuburn$8K
- Megan RichardsBangor$4K
- Brigham McKenneySouth Portland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.